CUMBERLAND PHARMACEUTICALS INC
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
CPIX$5.37+2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Valuation and Qualifying Accounts
Schedule II
Valuation and Qualifying Accounts
Years ended December 31, 2025 and 2024.
| Description · Balance atbeginning ofperiod · Charged tocosts andexpenses · Charged tootheraccounts · Deductions · Balance atend of period | ||||||
|---|---|---|---|---|---|---|
| Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products: | ||||||
| For the years ended December 31: | ||||||
| 2024 | 579,562 | 5,734,792 | 104,000 | (5,381,391) | 1,036,963 | |
| 2025 | 1,036,963 | 6,081,022 | 10,600 | (5,938,517) | 1,190,068 | |
| Valuation allowance for deferred tax assets: | ||||||
| For the years ended December 31: | ||||||
| 2024 | 21,869,328 | 80,010 | 21,949,338 | |||
| 2025 | 21,949,338 | 128,879 | — | — | 22,078,217 | |
(1) Composed of actual returns and credits for chargebacks and cash discounts.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.